About AFFiRiS
AFFiRiS is a company based in Vienna (Austria) founded in 2003 by Frank Mattner. It operates as a HealthTech and Licensing Model. AFFiRiS has raised $82.65 million across 7 funding rounds from investors including The Michael J. Fox Foundation, MIG Capital and Santoholding. AFFiRiS offers products and services including AFFITOPE®AT04, PD01, and PD01A. AFFiRiS operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Vienna, Austria
- Founders Frank Mattner
- SectorsHealthcare
- Phone•••• ••••
- Website affiris.com
- Social LinkedIn X
- Legal Name Affiris Ag
- Total Equity Funding$82.65M (USD)
in 7 rounds
- Latest Funding Round$10.9M (USD), Series B
May 2017
- InvestorsThe Michael J. Fox Foundation
& 2 more
Products & Services of AFFiRiS
AFFiRiS offers a comprehensive portfolio of products and services, including AFFITOPE®AT04, PD01, and PD01A.
Immunotherapy targeting PCSK9 to treat hypercholesterolemia effectively.
Immunotherapy developed for Parkinson’s disease treatment and management.
Immunotherapy targeting Parkinson’s disease with promising clinical results.
Funding Insights of AFFiRiS
AFFiRiS has successfully raised a total of $82.65M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $10.9 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $82.65M
- Total Rounds 7
- Last Round Series B — $10.9M
- First Round $10.43M
(Apr 2006)
- Investors Count 3
All 7 funding rounds of AFFiRiS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $10.9M | Series B | – | MIG Capital | – |
| Jun 2016 | $11.28M | Series B | – | MIG Capital | – |
| Jun 2015 | $11.23M | Series B | – | MIG Capital, Santo Holding | – |
| Nov 2011 | $34.41M | Series B | – | MIG Capital | – |
| Oct 2011 | $1.5M | Grant | – | – | |
| Sep 2008 | $4.4M | Series A | – | MIG Capital | – |
| Apr 2006 | $10.43M | Series A | – | MIG Capital | – |
3 investors in total: 3 institutional.
Investors in AFFiRiS
AFFiRiS has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation, MIG Capital and Santoholding.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC Firm funding companies in Europe | – | mig.ag | Munich, Germany | |
Santoholding is based in Zug, Switzerland, with limited information. | – | santoholding.ch | Zug, Switzerland | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States |
Investor details for AFFiRiS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AFFiRiS
10 people are tracked at AFFiRiS (5 in leadership, 5 in board & advisors).
| Name | Role | Group |
|---|---|---|
Frank Mattner | Founder | Leadership |
Noel Barrett | CEO | Leadership |
Claus Schalper | CEO | Leadership |
Petra Lührs | COO | Leadership |
Martina Hopitzan | Head of Finance & Administration | Leadership |
Michael Motschmann | Chairman | Board & advisors |
Klaus Schollmeier | Supervisory Board Member | Board & advisors |
Helmut Jeggle | Vice Chairman | Board & advisors |
Günther Staffler | Advisor | Board & advisors |
Rossella Medori | Advisor | Board & advisors |
Complete people profiles for AFFiRiS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AFFiRiS
3 dated milestones of AFFiRiS across 14 years, from founding to its latest funding, stage changes and deals.
- Founded AFFiRiS is founded.
- Funding First funding round of $10.4M.
- Funding Latest funding round, Series B, of $10.9M.
Competitors of AFFiRiS
AFFiRiS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| entradatx.com | 2016 | Boston, United States | $175.25M | 122 | Biologics platform developed for intracellular delivery in rare diseases. | |
| adamaspharma.com | 2002 | Emeryville, United States | $68.03M | 142 | Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. | |
| sonomabio.com | 2012 | San Francisco, United States | $335M | 74 | T-cell-based therapies for autoimmune and degenerative diseases are developed. | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| intracellulartherapies.com | 2002 | New York, United States | $80.87M | 600 | Developer of therapeutics for psychiatric and neurologic diseases | |
| juvlabs.com | 2017 | Dublin, Ireland | $289.89M | – | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. |
Detailed competitors of AFFiRiS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AFFiRiS
Websites that share an audience with AFFiRiS (affiris.com).
Websites whose visitors overlap most with AFFiRiS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
phytopharm.com | phytopharm.com | 100% | – | – | – |
biodeutschland.org | biodeutschland.org | 99% | – | #5,560,050 | – |
| amgen.com | 98% | 495.4K | #116,434 | View details | |
reseau-chu.org | reseau-chu.org | 60% | – | – | – |
| michaeljfox.org | 59% | 376.6K | #104,844 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for AFFiRiS
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Affiris
Complete news archive for AFFiRiS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to AFFiRiS
10 companies that operate in the same segment as AFFiRiS (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AFFiRiS
AFFiRiS was founded in 2003 and raised its 1st funding round 3 years after it was founded.
AFFiRiS is headquartered in Vienna, Austria.
Noel Barrett is the current CEO of AFFiRiS.
AFFiRiS is a funded company, having raised a total of $82.65M across 7 funding rounds to date. The company's 1st funding round was a Series A of $10.43M, raised on Apr 2006.
AFFiRiS, a clinical-stage biopharmaceutical company, is dedicated to the development of specific active immunotherapies (SAIT) for chronic human diseases using its proprietary AFFITOME technology. The company targets unmet medical needs in areas such as hypercholesterolemia and neurodegenerative diseases like Parkinsons and Multiple System Atrophy. Solutions are designed to stimulate the bodys immune response against proteins central to disease progression, offering potential for less frequent dosing regimens. Research and clinical trials are conducted to validate the efficacy of these therapies, aiming to improve patient outcomes in chronic disease management.
AFFiRiS's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
AFFiRiS offers AFFITOPE®AT04, PD01, and PD01A.
AFFiRiS has 3 investors. Key investors include The Michael J. Fox Foundation, MIG Capital, and Santoholding.
AFFiRiS operates through Affiris Ag.